Clonal Mesenchymal Stem Cell Generation Serum-Free
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and differentiating mesenchymal stem cells (MSCs) face challenges such as the need for invasive procedures, difficulty in maintaining long-term cultures without contamination, and reliance on serum-containing media, which introduces risks of infection and variation among batches.
Innovation Solution
A method for generating clonal MSCs involves culturing a heterogeneous single-cell suspension in serum-free, semi-solid medium with bFGF, followed by expansion in serum-free liquid medium, using techniques like co-culturing pluripotent cells with bone marrow stromal cells and depleting non-derived cells to obtain a substantially pure clonal population, characterized by specific markers and differentiation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serum-containing media is used for culturing MSCs, then cell proliferation is supported, but contamination risks and batch variation increase
Solution Approach 1:
The patent changes the chemical composition parameters of the culture medium by replacing serum with a chemically defined serum-free medium containing specific growth factors (bFGF, TGF-β1, IGF-1) and supplements (insulin, transferrin, selenium). This parameter change eliminates contamination risks associated with serum while maintaining cell proliferation through controlled addition of pure growth factors.
Solution Approach 2:
The patent employs a chemically defined medium formulation that can be prepared fresh or stored without degradation of critical components, replacing the need for batch-produced serum that varies between lots. This disposable-like approach ensures consistency and eliminates batch variation while supporting sustained cell growth.
2Quantity of substance
If invasive procedures are used to isolate MSCs from adult tissues, then sufficient cells can be obtained, but donor risks increase
Solution Approach 1:
The patent uses bone marrow stromal cells as intermediary feeder cells to support the growth and differentiation of embryonic stem cell-derived mesenchymal progenitors. This intermediary system allows expansion of MSCs without requiring invasive harvesting from adult donors, as the stromal cells provide necessary growth factors and structural support in vitro.
Solution Approach 2:
The patent performs preliminary differentiation of embryonic stem cells into mesenchymal progenitors before expansion, using predefined culture conditions and growth factor combinations. This preliminary action establishes the correct cell lineage early, enabling subsequent robust proliferation without needing to harvest from adult tissues through invasive procedures.
3Adaptability or versatility
If heterogeneous cell suspensions are cultured, then various cell types can be obtained, but clonal purity is reduced
Solution Approach 1:
The patent segments the heterogeneous cell suspension into individual single cells and plates them at low density to form isolated colonies. Each colony arises from a single mesenchymal progenitor cell, ensuring clonal purity. The segmentation approach allows subsequent selection and expansion of pure clonal lines while maintaining the ability to generate diverse cell types from different clones.
Solution Approach 2:
The patent creates local microenvironments around individual colonies with specific growth factor concentrations and stromal cell interactions that promote mesenchymal lineage commitment. This local quality control ensures that each clone develops uniform characteristics appropriate for its lineage while maintaining overall diversity across different clones.
Data Source
AI summary
Methods for obtaining multipotent mesenchymal stem cells under serum-free conditions and methods for identifying multipotent mesenchymal progenitor cells are disclosed.